Experimental and clinical psychopharmacology
November 1, 2006
Michelle R Lofwall, Roland R Griffiths, Miriam Z Mintzer
57 citations
Ketamine, a drug that blocks NMDA receptors, produces selective, temporary, dose- and time-related effects on memory and cognition. In a double-blind, placebo-controlled crossover study, 18 healthy adults received low or moderate doses of ketamine. Ketamine impaired memory encoding (free recall) and working memory speed, but spared retrieval, recognition, source memory, attention, and accuracy on a symbol substitution task. Subjective effects lasted longer than memory or psychomotor impairments, and there were no hallucinations or mystical experiences. The findings help clarify the role of NMDA receptors in different cognitive processes.
Experimental and clinical psychopharmacology
May 1, 1997
I Moroz, L A Parker, S Siegel
11 citations
A single injection of ibogaine given 24 hours before amphetamine prevented the formation of a conditioned place preference for amphetamine after one or two conditioning trials, but was less effective after four trials. The reduced effectiveness with more trials appears due to tolerance developing to ibogaine.
Experimental and clinical psychopharmacology
October 1, 2024
Kaitlyn J Partridge, Todd M Hillhouse
1 citation
Digging behavior in mice is a stable and consistent compulsive-like behavior that can be reduced by both behavioral and pharmacological stressors, producing a depression-like state. A single swim stress significantly reduced digging for at least three days, with recovery by day seven. Repeated treatment with fluoxetine (10 mg/kg/day), but not ketamine, partially reversed swim stress-induced digging suppression on days three and seven. The pharmacological stressor yohimbine dose-dependently decreased digging, and repeated ketamine (10 mg/kg/day), but not fluoxetine, reversed yohimbine-induced digging suppression. These results indicate that stress-induced suppression of digging behavior is stimulus- and drug-dependent, requiring further investigation.
Experimental and clinical psychopharmacology
July 24, 2025
Shahar Almog, Maribel Rodriguez Perez, Deepthi S Varma et al.
In a survey of 201 patients receiving medical ketamine for psychiatric or pain conditions, most reported either a positive change (54.7%) or no change (44.3%) in their use of other substances. Those with a past history of problematic substance use showed significantly greater reductions than those with present or no such history. Patients described reduced craving, less need to self-medicate, and increased motivation to quit substances. Ketamine did not appear to induce or increase drug use among those with minimal or no prior use, though some reported risky behaviors such as using other psychedelics or substituting alcohol with recreational ketamine. Further research is needed to identify and protect at-risk patients.